• English
  • Korean
  • Chinese
表紙
市場調査レポート - 203833

世界の幹細胞技術市場展望

Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025

発行 Visiongain
出版日 ページ情報 英文 262 Pages
価格

ご注意: Single UserとDepartmentalライセンスは、DRM(デジタル著作権管理システム)付PDFになります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。
2014/10/31以降の購入分から、閲覧期限は購入日より1年となります。

世界の幹細胞技術市場展望 Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025
出版日: ページ情報: 英文 262 Pages
概要

幹細胞製品およびサービスは投資、技術進歩および販売において大きな可能性があります。世界の幹細胞技術市場は2013年から2023年に高成長を達成し、2017年には107億米ドルに達すると予測されています。

当レポートでは、幹細胞の治療応用、技術動向、製品、サービス概要をまとめ、セグメント別の予測などを提供しており、SWOT分析、専門家の見解とともに、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 幹細胞技術の概要

  • 強い市場実績の予測
  • 癌セグメントは幹細胞療法収益のほとんどを示す
  • どのタイプの幹細胞が市場にとって重要か?
  • 世界の幹細胞規制環境

第3章 幹細胞治療セグメント

  • HSCTは癌セグメントの成長を支える見込み:2013年〜2023年
  • 幹細胞:血液癌治療の主要部分としての45年
  • 最初の認可によるパイプラインの成熟
  • 癌適応症において幹細胞はどれだけの成長潜在性を持っているか?

第4章 幹細胞心血管治療セグメント

  • セグメントはCAGR40%以上の見込み:2013年〜2023年
  • 幹細胞は心臓・血管系を治せるか?
  • 心血管幹細胞パイプライン・製品
  • 幹細胞は心血管の領域におけるゲームチェンジャーとなるか?

第5章 幹細胞CNS(中枢神経系)治療セグメント

  • 最大の幹細胞療法革命の全ては2023年までに形成され始める
  • 幹細胞は多くの深刻なCNS疾患にとって最大の望み
  • CNSにおける最初の第3層試験となるのはどの製品か?
  • CNS幹細胞は認められた治療可能性を実現できるか?

第6章 その他の疾病領域における幹細胞治療

  • 多様な認可範囲がセグメントの成長を後押し
  • 幹細胞治療のその他の適応症
  • どの適応症が最初に認可されるか?
  • 2023年までにその他の治療領域で幹細胞の臨床における飛躍的進歩を期待できるか?

第7章 幹細胞技術セグメントの非治療アプリケーション

  • セルベースアッセイは同セグメントの拡大を助ける
  • 新興する多様な範囲のビジネスモデル
  • 非治療幹細胞活動にとっての主要な成長領域は?

第8章 産業の定性分析

  • 強み:幹細胞は遂にその価値を証明
  • 弱み:克服すべき多くの問題が残る
  • 機会:幹細胞はかつてない臨床的可能性を持つ
  • 脅威:規制・商業的不安点性が市場を脅かす
  • 社会的懸念事項:賛否両論の技術
  • 技術的発展:幹細胞科学は発展途上
  • 経済要因:資金不足の心配
  • 政治的問題:研究開発には州の態度が鍵

第9章 調査インタビュー

第10章 結論

  • 幹細胞技術は2017年までに飛躍的進歩が始まる
  • 市場は2023年まで2桁のCAGRを記録する
  • 2017年まで癌・非治療用途が支配的
  • 2023年までにCNS・心血管治療が市場シェアを獲得する
  • 強いR&Dパイプラインが市場成長を促進する
  • 長期的には幹細胞の根本的な臨床的・商業的可能性
  • 幹細胞市場の課題
  • 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Stem cells, an expanding market with vast potential - explore developments and commercial prospects

What does the future hold for that cellular technology? What progress and sales are possible? There avoid struggles to gain business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.

Visiongain's new investigation gives you revenue forecasts to 2025 for the world stem cells market, submarkets and leading products. Avoid missing out. There see what's happening for those cell-based technologies and uses, discovering the most lucrative applications.

See what gains are possible. Please read on, then, to explore that industry and discover what its future market could be worth.

Forecasts and other analyses showing opportunities in those cellular technologies

Besides revenue forecasting to 2025, our analyses show recent results, growth rates and market shares. There you find original analysis. Also that work lets you assess research and development. And there gain 55 tables, 38 charts and six interviews with organisations.

Now make your searching for data on stem cells easier. Also save time. And benefit your insight and authority. Our study's purpose is to help in research, analysis and decisions, helping you discover where developments and money lie, staying ahead in knowledge.

And the following sections highlight what's in that technology, industry and market survey.

Prospects for the overall world market and segments - what's possible?

What're the secrets of that industry's progress? Along with our prediction of the overall world market value for stem cells, our work shows you individual revenue forecasting of five submarkets to 2025 at world level, with discussions:

  • Cancer (oncology)
  • Central nervous system (CNS) disorders
  • Cardiovascular diseases
  • Other medical treatments
  • Non-therapeutic uses.

Which segment can achieve highest sales? Which has fastest predicted growth? See how and why those commercial uses in healthcare can develop, prosper and gain in importance.

For developers, producers and sellers, assess how those tools, systems and applications earn money. And gauge their potential success from this decade onwards.

Products - discover sales forecasting of leading agents

Our study also shows you individual revenue predictions to 2025 for six top brands:

  • Prochymal (Mesoblast)
  • Hearticellgram-AMI (Pharmicell)
  • CardioRel (Reliance Life Sciences)
  • Osteocel Plus (NuVasive)
  • Trinity Elite and Evolution (Orthofix)
  • Cartistem (Medipost).

There you discover prospects for established and emerging technology and medicines. That market will grow through the approval and launch of many products from this decade.

Our study explains, looking ahead, discussing issues to help your work.

Developments, challenges and opportunities affecting researchers, producers and users

Our investigation lets you assess trends, R&D and outlooks for stem cell technology. There you find discussions of forces, progress and potential:

  • Developments in the US, Japan, Europe, South Korea, China, India and Israel, with regulations, achievements, regional prominence and outlooks
  • Activities of Mesoblast, Pharmicell, NuVasive, Orthofix, Medipost, Advanced Cell Technology, Athersys, Novartis, GSK and other organisations, private and public
  • Approvals of therapies and other products to expand and advance that industry
  • Japan's accelerated marketing authorisation for promising treatments
  • Regenerative medicine and uses in diabetes, liver degeneration, Crohn's disease, diabetes, rheumatoid arthritis and other medical conditions.

That study discusses other influences, including these:

  • Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
  • Autologous versus allogeneic cellular agents - possibility for universal products
  • Haematopoietic stem cell transplantation (HSCT)
  • Uses for umbilical cord blood and related technologies, including cellular banking
  • Treatments for orphan diseases and difficult-to-cure disorders
  • Agents for osteogenesis and treating autoimmune conditions
  • Applications in cell-based assays, diagnostics and drug development.

There you explore political, economic, social and technological questions, assessing advances and prospects. You also gain regulatory insights. That way you investigate what helps and restrains those developers, producers and marketers.

Discover there what the past, present and future hold.

Stem cells - what's next, and world 2018 market value?

From 2014 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for stem cells will reach $12bn in 2018, achieving high revenue growth from 2015 to 2025.

That study's author said: "Therapies in myocardial infarction, heart failure and other prominent diseases have reached phase III trials, suggesting the stem cells market will achieve rapid growth during the middle of our forecast period.

"Clinical-stage companies there focus on CNS disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. They also tackle ophthalmic conditions, including age-related macular degeneration (AMD)."

Prospects for those medical systems and tools are strong, and from 2015 there will arise many opportunities. Our work shows you the possibilities, helping you stay ahead.

Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025 shows information found nowhere else

In particular you gain these analyses to help your research, assessments and decisions:

  • Overall world revenue to 2025 - see the results and sales potential of that industry
  • Five submarkets' revenues to 2025 - investigate segments at world level, finding the most lucrative applications
  • Six product revenues to 2025 - discover sales predictions for top medical agents, seeing how they can succeed, including what helps and limits their performance
  • R&D on stem cells - investigate progress, finding technological, clinical and commercial outlooks, including products expected in the next 10 years
  • Activities of established, rising and emerging companies - hear about firms' capabilities, portfolios, advances and prospects
  • Interviews with six organisations - explore views to help your work, getting feel for that sector and its participants
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.

Potential for stem cells - discover now what's possible worldwide from 2015

There you receive business intelligence found only in our work, discovering where money, progress and opportunities lie. That way you can benefit your influence and reputation for insight.

With our new study you're less likely to miss opportunity or fall behind. Instead stay ahead for knowledge. You explore trends, R&D and sales predications, with discussions. So please get our report here now.

Table of Contents

1. Report Overview

  • 1.1 Global Stem Cell Technologies and Applications Market Overview
  • 1.2 Global Stem Cell Technologies and Applications Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Stem Cell Technologies and Applications

  • 2.1 What are Stem Cells?
  • 2.2 Timeline of Stem Cell Research
    • 2.2.1 Embryonic Stem Cells (ESCs) Enter the Picture
  • 2.3 Classifying Stem Cells by Potency
    • 2.3.1 Stem Cell Categories: ESCs, SSCs, IPSCs
    • 2.3.2 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
    • 2.3.3 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?
    • 2.3.4 Advantages and Disadvantages of Different Cell Types
  • 2.4 Regulation of Stem Cell Research
    • 2.4.1 Regulation in the US
      • 2.4.1.1 Understanding 'Homologous Use'
      • 2.4.1.2 Embryonic Stem Cell Research Remains Controversial
      • 2.4.1.3 FDA v Regenerative Sciences: Regulating MSC Therapy
    • 2.4.2 Regulation in Europe
      • 2.4.2.1 The Brüstle Ruling: Dead and Buried?
      • 2.4.2.2 The UK Leads in European Stem Cell R&D
    • 2.4.3 Regulation in Japan
    • 2.4.4 Regulation in Other Regions
      • 2.4.4.1 South Korea Paves a Path for MSC Therapies
      • 2.4.4.2 Liberal Chinese Laws for Stem Cell Research
      • 2.4.4.3 Israel: A Strong Presence in Stem Cell Research
      • 2.4.4.4 India: An Emerging Stem Cell Industry
  • 2.5 Phases of Clinical Trials
  • 2.6 Scope of this Report
  • 2.7 Currency Exchange Rates in This Report

3. Stem Cell Technologies and Applications: World Market 2015-2025

  • 3.1 The World Stem Cell Technologies and Applications Market in 2014
  • 3.2 World Stem Cell Technologies and Applications Market: Regional Breakdown, 2014
  • 3.3 Stem Cell Technologies and Applications Market Segmentation, 2014
  • 3.4 Stem Cell Technologies and Applications Market: Sales Forecast 2015-2025
  • 3.5 Stem Cell Technologies and Applications Market: Sales Forecast by Segment, 2015-2025
  • 3.6 How Will Segmental Market Shares Change to 2025?
  • 3.7 Non-Therapeutic Applications Lead the Stem Cell Technologies and Applications Market
  • 3.8 Stem Cell Technologies and Applications Market: Drivers and Restraints 2015-2025
  • 3.9 Recent Developments
    • 3.9.1 STAP Cell Scandal in Japan
    • 3.9.2 Tracheal Transplant Patient Dies
    • 3.9.3 Stem Cell Rush in Japan after Regulatory Changes?

4. Stem Cell Cancer Therapeutics Segment 2015-2025

  • 4.1 Stem Cell Cancer Therapeutics: Overview
  • 4.2 The Stem Cell Cancer Therapeutics Market in 2014
  • 4.3 Stem Cell Cancer Therapeutics: Market Forecast 2015-2025
  • 4.4 Haematopoietic Stem Cell Transplantation (HSCT)
    • 4.4.1 An Established Treatment for Haematological Cancers
    • 4.4.2 Autologous HSCT Continues to Dominate
    • 4.4.3 Allogeneic HSCT: More Rejections, Fewer Relapses
    • 4.4.4 GvHD: The Major Issue for HSCT
    • 4.4.5 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
    • 4.4.6 The Rise of Umbilical Cord Blood
    • 4.4.7 80,000 HSCT Operations Performed Worldwide in 2014
    • 4.4.8 HSCT Costly, Medicare Coverage Selective
    • 4.4.9 Haematological Malignancies are the Major Indication for HSCT
  • 4.4.10 HSCT Addresses Cancers Representing a $20bn Market
  • 4.5 From Procedures to Products: Cord Blood Stem Cell Approvals
    • 4.5.1 Hemacord (New York Blood Center)
    • 4.5.2 HPC, Cord Blood (ClinImmune/University of Colorado Cord Blood Bank)
    • 4.5.3 Ducord (Duke University School of Medicine)
    • 4.5.4 Allocord (SSM Cardinal Glennon Children's Medical Center)
    • 4.5.5 HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
  • 4.6 Stem Cell Cancer Therapeutics: Pipeline Review 2015-2025
    • 4.6.1 Apceth: Genetically Modified MSCs for Gastrointestinal Cancer
    • 4.6.2 Athersys: MultiStem in Haematological Malignancies
    • 4.6.3 Cellerant Therapeutics: CLT-008 and CLT-009
    • 4.6.4 Cynata Therapeutics: Mass Producing MSCs for GvHD?
    • 4.6.5 Fate Therapeutics: Modified HSCs for Haematological Malignancy
    • 4.6.6 Gamida Cell: Shifting Focus from StemEx to NiCord
      • 4.6.6.1 Survival at 100 Days Improved by StemEx in Latest Trial
      • 4.6.6.2 NiCord Heads Up a Pipeline of Novel Cell Therapies
      • 4.6.6.3 Novartis in Talks to Acquire Gamida Cell
    • 4.6.7 ImmunoCellular Therapeutics: Stem Cells for Cancer Immunotherapy
    • 4.6.8 Mesoblast: Using Mesenchymal Precursors to Enrich Cord Blood
      • 4.6.8.1 Prochymal (remestemcel-L/MSC-100-IV, Mesoblast): Limited Market Access
      • 4.6.8.2 The Development of Prochymal
      • 4.6.8.3 Success in Subsets of GvHD Patients
      • 4.6.8.4 An Important Role to Play in the Future of HSCT
      • 4.6.8.5 Prochymal: Sales Forecast 2015-2025
      • 4.6.8.6 Phase 3 Trial in Haematological Malignancies
      • 4.6.8.7 A Competitor for Gamida Cell?
    • 4.6.9 Novartis Developing Cord Blood Transplant Candidates
      • 4.6.9.1 HSC835 Expanding Umbilical Cord Blood
      • 4.6.9.2 Novartis Partners with Regenerex for Cell-Based Therapies
  • 4.7 Other Stem Cell Oncology Prospects
    • 4.7.1 Ancillary Products for the HSCT Setting
    • 4.7.2 Targeting Cancer Stem Cells (CSCs)
    • 4.7.3 Immunovative Therapies: Building on HSCT for a Cellular Anti-Cancer Therapy
  • 4.8 Stem Cell Cancer Therapeutics: Drivers and Restraints 2015-2025

5. Stem Cell Cardiovascular Therapeutics Segment 2015-2025

  • 5.1 Stem Cell Cardiovascular Therapeutics: Overview
  • 5.2 The Stem Cell Cardiovascular Therapeutics Market in 2014
  • 5.3 Stem Cell Cardiovascular Therapeutics: Market Forecast 2015-2025
  • 5.4 Cardiovascular Diseases Dominate the Global Pharmaceutical Market
    • 5.4.1 Cardiovascular and Cerebrovascular Conditions Are the World's Most Fatal Diseases
    • 5.4.2 AMI, CLI and Stroke: Major Ischaemic Disease Targets
  • 5.5 The State of Stem Cell Research for Cardiovascular Diseases
    • 5.5.1 Can Stem Cells Heal the Heart and Vasculature?
    • 5.5.2 Stem Cell Treatments for Stroke
    • 5.5.3 Defining Cardiovascular Stem Cells
  • 5.6 Safety and Efficacy of MSCs in Clinical Trials
    • 5.6.1 The Mysterious Efficacy of Adult Stem Cells in the Heart
    • 5.6.2 Therapeutic Effects Despite Rapid Clearance
    • 5.6.3 Doubts over the Efficacy of MSCs in the Heart
    • 5.6.4 Looking Beyond MSCs
  • 5.7 Stem Cell Cardiovascular Therapeutics in the Market
    • 5.7.1 Pharmicell: Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
      • 5.7.1.1 Hearticellgram-AMI Sales 2012-2013
      • 5.7.1.2 Difficulty Accessing Markets Outside South Korea
      • 5.7.1.3 Hearticellgram-AMI: Sales Forecast 2015-2025
      • 5.7.1.4 Pharmicell: Pipeline Products
    • 5.7.2 Reliance Life Sciences: CardioRel
  • 5.8 Stem Cell Cardiovascular Therapeutics: Pipeline Review 2015-2025
    • 5.8.1 Cytomedix Rebrands as Nuo Therapeutics, Exits Stem Cell R&D
    • 5.8.2 Aastrom Biosciences (Vericel Corporation): Ixmyelocel-T
      • 5.8.2.1 New Focus on Dilated Cardiomyopathy
    • 5.8.3 Apceth: MSCs for Advanced Peripheral Vascular Disease
    • 5.8.4 Arteriocyte: Nanex Technology to Treat CLI
    • 5.8.5 Athersys: MultiStem in Stroke and Acute Myocardial Infarction
    • 5.8.6 Baxter: Phase 3 in Refractory Angina
    • 5.8.7 BioCardia: MSC Therapies for Heart Failure and AMI
    • 5.8.8 Biogenea-Cellgenea: Still Developing Cardiogenea?
    • 5.8.9 Bioheart: Phase 3 in Heart Failure, But Needs Extra Funding
      • 5.8.9.1 Seeking Expanded Access for Compassionate Use
    • 5.8.10 Capricor: Cardiosphere-Derived Cells for Heart Repair
    • 5.8.11 Cardio3 BioSciences: Cardiopoiesis for Heart Regeneration
    • 5.8.11.1 Phase 3 Trial Begins Amid Controversy
    • 5.8.12 CellProthera: Myocardial Tissue Regeneration
    • 5.8.13 Cytori Therapeutics: Stem Cells for Acute Myocardial Infarction
    • 5.8.14 Human Stem Cells Institute: Developing Gemacell and Cryocell
    • 5.8.15 Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
      • 5.8.15.1 CEP-41750 Moving to Phase 3 in Congestive Heart Failure
      • 5.8.15.2 Phase 2 in Acute Myocardial Infarction
      • 5.8.15.3 Promising Preclinical Findings in Ischaemic Stroke
      • 5.8.15.4 Teva Collaborating on Cardiovascular Stem Cell Therapy R&D
    • 5.8.16 NeoStem: Diversified Outfit with One of the Leading Candidates
      • 5.8.16.1 NBS10 to Treat Acute Myocardial Infarction
    • 5.8.17 Stemedica Cell Technologies: Ischaemic-Tolerant Stem Cell Platform
      • 5.8.17.1 Phase 2 in Acute Myocardial Infarction, Ischaemic Stroke, Heart Failure and Cutaneous Photoaging
    • 5.8.18 Stempeutics: Emerging Indian Company Targets CLI
    • 5.8.19 Other Stem Cell Cardiovascular Prospects
  • 5.9 Can Stem Cells Change The Treatment Paradigm for Cardiovascular Disease?

6. Stem Cell Central Nervous System Therapeutics Segment 2015-2025

  • 6.1 Stem Cell Central Nervous System Therapeutics: Overview
  • 6.2 The Stem Cell Central Nervous System Therapeutics Market in 2014
  • 6.3 Stem Cell Central Nervous System Therapeutics: Market Forecast 2015-2025
  • 6.4 The State of Stem Cell Research in CNS Diseases
    • 6.4.1 Stem Cells the Best Hope for Many Serious CNS Conditions
    • 6.4.2 Awaiting a First Breakthrough Approval
    • 6.4.3 Human NSCs Successfully Isolated
    • 6.4.4 NSCs Reach the Clinic
    • 6.4.5 CNS Disorders are the Major Focus for ESC Research
    • 6.4.6 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
  • 6.5 Progress in Specific CNS Conditions
    • 6.5.1 HSCT in MS: Could 'Resetting' the Immune System Treat MS?
    • 6.5.2 ALS: Rare Disease Could be the First Neurodegenerative Condition for Stem Cell Treatment
    • 6.5.3 Parkinson's Disease: Moratorium on Stem Cell Research Ends
    • 6.5.4 Dry Age-Related Macular Degeneration: A Major Unmet Need
    • 6.5.5 Several Multi-Billion Dollar Potential Markets in the Sights of CNS Stem Cell Developers
  • 6.6 Stem Cell Central Nervous System Therapeutics: Pipeline Review 2015-2025
    • 6.6.1 Advanced Cell Technology: Stem Cells for Eye Diseases
      • 6.6.1.1 Stargardt's Macular Degeneration: Moving to Phase 2
      • 6.6.1.2 Early Signals of Efficacy, or Confounded Results?
      • 6.6.1.3 Advancing to Phase 2 in Dry AMD
    • 6.6.2 Athersys: Multistem for Ischaemic Stroke
    • 6.6.3 BrainStorm Cell Therapeutics: Neurotrophic Factor-Releasing Stem Cells for ALS
    • 6.6.3.1 Phase 2 Trial in 48 ALS Patients Underway
    • 6.6.4 Cellonis Biotechnologies: Switching From Diabetes to Stroke
    • 6.6.5 Corestem: MSCs for ALS
    • 6.6.6 International Stem Cell Corporation: Preclinical CNS Treatments
    • 6.6.7 InVivo Therapeutics: Neuro-Spinal Scaffold for Spinal Cord Injury
    • 6.6.8 Mesoblast: Phase 2 in Wet AMD, Preclinical in Neurology
    • 6.6.9 Neuralstem: Allogeneic Neural Stem Cells for Synaptic Repair and Neuroprotection
      • 6.6.9.1 Long-Term Follow-Up Data is Promising in ALS
      • 6.6.9.2 Chronic and Acute Spinal Cord Injury Treatment to Follow
      • 6.6.9.3 Ischaemic Stroke: Phase 1/2 Trials Underway in China
    • 6.6.10 Preclinical Work in Other Neurological Disorders
    • 6.6.11 NeuroGeneration: Investigating Human NSCs
    • 6.6.12 Pfizer: Collaborating on the London Project to Cure Blindness
    • 6.6.13 Q Therapeutics: Glial-Based Stem Cells as an ALS Treatment
    • 6.6.14 ReNeuron: ReN001 is Demonstrating Potential in Stroke
      • 6.6.14.1 Foetally-Sourced Cells Have Wide Potential Application
    • 6.6.15 RhinoCyte: Stem Cells from the Nasal Passage to the Spinal Cord
    • 6.6.16 SanBio: SB623 for Ischaemic Stroke
      • 6.6.16.1 Future SanBio Programmes at Preclinical Stage in 2014
    • 6.6.17 StemCells: a Leader in Neural Stem Cells
    • 6.6.17.1 HuCNS-SC Product Proving Itself in Rare Indications
      • 6.6.17.2 Moving on to Spinal Cord Injury and AMD
      • 6.6.17.3 Alzheimer's Disease and Stroke to Follow?
  • 6.7 Other Companies with Technologies of Interest
    • 6.7.1 iPierian - Bringing IPSCs to the CNS Market?
    • 6.8 Stem Cell CNS Therapeutics: Drivers and Restraints 2015-2025

7. Stem Cell Therapeutics in Other Disease Areas 2015-2025

  • 7.1 Stem Cell Therapeutics in Other Disease Areas: Overview
  • 7.2 Stem Cell Therapeutics in Other Disease Areas: The Market in 2014
  • 7.3 Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2015-2025
  • 7.4 Stem Cell Therapeutics for Other Diseases in the Market
    • 7.4.1 Osteocel Plus (NuVasive): The Leading Stem-Cell Orthobiologic
      • 7.4.1.1 Osteocel to Osteocel Plus: A Chequered History
      • 7.4.1.2 Better than Autograft?
      • 7.4.1.3 Osteocel Plus: Sales Forecast 2015-2025
    • 7.4.2 Trinity Elite and Evolution (Orthofix): Second-Generation Stem Cell Orthobiologics
      • 7.4.2.1 Trinity Elite and Evolution: Sales Forecast 2015-2025
    • 7.4.3 Cartistem (Medipost): 'World's First Allogeneic Stem Cell Drug'
      • 7.4.3.1 Cartistem: Sales Forecast 2015-2025
    • 7.4.4 LiquidGen (Skye Orthobiologics): Liquid Amniotic Allograft
    • 7.4.5 AlloStem (Allosource)
    • 7.4.6 Map3 (RTI Surgical)
  • 7.5 Stem Cell Therapeutics for Other Diseases: Research Areas
    • 7.5.1 HSCT for Orphan Diseases
    • 7.5.2 Genetically Modified Stem Cells for HIV and Other Diseases
    • 7.5.3 Stem Cells Are Osteogenic
    • 7.5.4 Perianal Fistula Treatment Indicates Stem Cells' Potential in Tissue Repair
    • 7.5.5 Autoimmune Disorders Offer Real Market Potential
    • 7.5.6 A Potential Cure for Diabetes?
    • 7.5.7 Stem Cells in Active Liver Repair
    • 7.5.8 Long-Range Possibilities
  • 7.6 Stem Cell Therapeutics in Other Disease Areas: Pipeline Review 2015-2025
    • 7.6.1 Alliancells Bioscience Corporation: Possible RA Treatment
    • 7.6.2 AlloCure: AC607 Phase 2 Study Terminated
    • 7.6.3 American CryoStem: ATCELL Preclinical Programmes
    • 7.6.4 Anterogen: South Korean Stem Cell Company
    • 7.6.5 Athersys: MultiStem Fails Phase 2 in Ulcerative Colitis
    • 7.6.6 BioRestorative Therapies: Exploring Disc Disease and Diabetes
    • 7.6.7 BioTime: Multiple Subsidiaries, Multiple Therapies
      • 7.6.7.1 Asterias Biotherapeutics: Neurology and Oncology
      • 7.6.7.2 Cell Cure Neurosciences: Phase 1/2a in Dry AMD
      • 7.6.7.3 OncoCyte: Cancer Diagnostics
      • 7.6.7.4 OrthoCyte: Orthopaedic Stem Cell Treatments
      • 7.6.7.5 ReCyte: ESCs and IPSCs for Cardiovascular Diseases
      • 7.6.7.6 Other BioTime Subsidiaries
    • 7.6.8 Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
    • 7.6.9 Celgene Cellular Therapeutics: Targeting Inflammatory Conditions
    • 7.6.10 Cellular Biomedicine Group: MSCs for Knee Osteoarthritis
    • 7.6.11 IntelliCell BioSciences: Adipose-Derived Stem Cells
    • 7.6.12 Life Stem Genetics: Adipose-Derived Stem Cells
    • 7.6.13 Medipost: Four Programmes in Development
    • 7.6.14 Medistem: Acquired by Intrexon
    • 7.6.15 Medistem Panama: Investigating MSCs
    • 7.6.16 Mesoblast: MPCs for Crohn's Disease, Diabetes and Rheumatoid Arthritis
      • 7.6.16.1 Prochymal in Crohn's Disease: Phase 3
      • 7.6.16.2 Allogeneic MPCs for Diabetes in Phase 2
      • 7.6.16.3 Allogeneic MPCs for Rheumatoid Arthritis in Phase 2
      • 7.6.16.4 Allogeneic MPCs in Intervertebral Disc Repair and Spinal Fusion: Phase 2
    • 7.6.17 Pluristem Therapeutics: Placental Stem Cells for Cardiovascular Diseases
    • 7.6.18 Regeneus: Taking Adipose-Derived MSCs into Clinical Trials
    • 7.6.19 S-Evans Biosciences: Menstrual Stem Cells for Hepatic Disease
    • 7.6.20 TiGenix: Expanded Adipose-Derived Stem Cell Therapies
      • 7.6.20.1 Cx601: Phase 3 Data Expected In July 2015
      • 7.6.20.2 Cx611: Phase 2 in Rheumatoid Arthritis
      • 7.6.20.3 Cx621: Intralymphatic Stem Cells for Autoimmune Diseases
      • 7.6.20.4 ChondroCelect Already on the Market
    • 7.6.21 ViaCyte: Revolutionising Diabetes Treatment with VC-01?
    • 7.6.22 ViroMed: Genetically Modified Stem Cells for Chronic Granulomatous Disease
  • 7.7 Genetically Modified Stem Cell Therapy Pipeline
    • 7.7.1 Bluebird Bio: Gene-Modified HSCs for Orphan Diseases
    • 7.7.2 GSK: Ex-Vivo Stem Cell Gene Therapies for Rare Diseases
    • 7.7.3 Sangamo BioSciences: Genetically Modified Stem Cells for HIV

8. Stem Cell Non-Therapeutic Applications 2015-2025

  • 8.1 Stem Cell Non-Therapeutic Applications: Overview
  • 8.2 Stem Cell Non-Therapeutic Applications Market in 2014
  • 8.3 Stem Cell Non-Therapeutic Applications: Market Forecast 2015-2025
  • 8.4 Stem Cell Banking: Growing Demand Worldwide
    • 8.4.1 Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
  • 8.5 Stem Cell Supply and Processing: IPSCs the New Driver
  • 8.6 Stem Cell-Based Assays: Major Potential for Preclinical Screens
  • 8.7 Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
  • 8.8 The Outlook for Non-Therapeutic Stem Cell Activities

9. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2015-2025

  • 9.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
  • 9.2 Strengths
    • 9.2.1 HSCT is an Established Procedure
    • 9.2.2 Recent Approvals of Stem Cell Therapies
    • 9.2.3 Relaxation of Regulatory Barriers
  • 9.3 Weaknesses
    • 9.3.1 Uncertain Mechanism of Action in Stem Cell Therapies
    • 9.3.2 Few Late-Stage Pipeline Products
    • 9.3.3 Regulatory and Reimbursement Concerns
  • 9.4 Opportunities
    • 9.4.1 Genetic Modification of Stem Cells
    • 9.4.2 Unmet Clinical Needs
    • 9.4.3 Non-Therapeutic Uses: Cord Banking and Cell-Based Assays
    • 9.4.4 Interactions with Related Technologies
  • 9.5 Threats
    • 9.5.1 Financial Risks
    • 9.5.2 Pipeline Failure
    • 9.5.3 Long-Term Safety Concerns
  • 9.6 STEP Analysis of the Stem Cell Technologies and Applications Market
  • 9.7 Social Factors
    • 9.7.1 Increasing Burden of Disease
    • 9.7.2 Biological Insurance through Stem Cell Banking
    • 9.7.3 Stem Cell Tourism: the Hype and the Hope
  • 9.8 Technological Factors
    • 9.8.1 Increasing Research Output
    • 9.8.2 IPSC Breakthroughs
    • 9.8.3 Greater Understanding of Stem Cell Differentiation
    • 9.8.4 Biomaterials, Bioprinting and Other Developments
    • 9.8.5 CRISPRs: A Breakthrough in Genome Editing
  • 9.9 Economic Factors
    • 9.9.1 Grey Market for Stem Cell Therapies
    • 9.9.2 Broad Changes in Pharma/Healthcare Markets
    • 9.9.3 The Business Model Needs Further Development
  • 9.10 Political Factors
    • 9.10.1 Ethical Objections to Embryonic Stem Cell Research
    • 9.10.2 Strong Support from National Governments
    • 9.10.3 Pressure to Deregulate the Stem Cell Therapies Market

10. Research Interviews

  • 10.1 Interview with Mr Brock Reeve, Executive Director, Harvard Stem Cell Institute, Massachusetts, US
    • 10.1.1 Recent Developments in Stem Cells
    • 10.1.2 Stem Cell Techniques and Therapies in 2015-2025
    • 10.1.3 Potential Applications of Genome Editing
    • 10.1.4 Therapeutic Areas for Stem Cell Therapies
    • 10.1.5 The Need for New Business Models?
    • 10.1.6 Developing the Stem Cell Therapy Market
    • 10.1.7 Other Trends and Developments
  • 10.2 Interview with Dr Mark Berman, Founder, Cell Surgical Network, US
    • 10.2.1 Cell Surgical Network: Stem Cell Therapies
    • 10.2.2 Cell Therapy as Investigative Treatment
    • 10.2.3 Promising Therapeutic Applications
    • 10.2.4 Future Developments for CSN and Stem Cell Therapies
    • 10.2.5 The Need for New Business Models?
    • 10.2.6 Regulatory Issues in Japan and Elsewhere
    • 10.2.7 The FDA and Cell Surgical Network
    • 10.2.8 Developing the Stem Cell Therapy Market
    • 10.2.9 Other Trends and Developments
  • 10.3 Interview with Dr Leonard Zon, Director of the Stem Cell Program at Children's Hospital Boston, Massachusetts, US
    • 10.3.1 Recent Developments in Stem Cells
    • 10.3.2 Research at Zon Laboratory
    • 10.3.3 Stem Cell Techniques and Therapies in 2015-2025
    • 10.3.4 The Need for New Business Models?
    • 10.3.5 Developing the Stem Cell Therapy Market
    • 10.3.6 Other Trends and Developments
  • 10.4 Interview with Dr Artur Isaev, General Director, Human Stem Cells Institute, Moscow, Russia
    • 10.4.1 Future Prospects for Cord Blood Stem Cell Banking
    • 10.4.2 Increasing Competition in Stem Cell Banking
    • 10.4.3 Progress with Gemacell and Cryocell
    • 10.4.4 Opportunities in Russia and Other Markets
    • 10.4.5 Challenges for Stem Cell Companies Over 2015-2025
    • 10.4.6 Developing the Stem Cell Therapy Market
    • 10.4.7 Other Trends and Developments
  • 10.5 Interview with Dr Alan Trounson, Emeritus Professor, Monash University, Melbourne, Australia
    • 10.5.1 Improved Funding in the Stem Cells Field
    • 10.5.2 MSCs: Major Potential or Merely a Placeholder?
    • 10.5.3 CIRM Investment Strategies
    • 10.5.4 The Changing Regulatory Environment Worldwide
    • 10.5.5 Key Trends for the Next Five to Ten Years
  • 10.6 Interview with Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
    • 10.6.1 Overview of the Current State of the IPSC Field
    • 10.6.2 Genomic Stability and Other Potential Issues for IPSCs
    • 10.6.3 Potential for Treating and Modelling Diseases with IPSCs
    • 10.6.4 Reprogramming Without Transgenes
    • 10.6.5 Possibilities for Directly-Converted Cells

11. Conclusions

  • 11.1 Stem Cell Technologies and Applications: An Emerging Market
  • 11.2 The Stem Cell Technologies and Applications Market in 2014
    • 11.2.1 Current Leading Stem Cell Technologies and Applications Segments
    • 11.2.2 Leading Regional Markets
  • 11.3 World Stem Cell Technologies and Applications Market Forecast 2015-2025
  • 11.4 Stem Cell Technologies and Applications Late-Stage Pipeline
  • 11.5 The Future of the Stem Cell Technologies and Applications Market
    • 11.5.1 Challenges for the Stem Cells Market
    • 11.5.2 Concluding Remarks

List of Tables

  • Table 2.1 Potency and Source of Stem Cells
  • Table 2.2 Germ Layers and Their Associated Types of Cells and Organs, 2014
  • Table 2.3 Main Types of Stem Cells and Their Properties, 2014
  • Table 2.4 Stem Cell Donor Terminology, 2014
  • Table 2.5 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2014
  • Table 2.6 Clinical Trial Phases
  • Table 2.7 Currency Exchange Rates, 2013 and 2014
  • Table 3.1 Stem Cell Technologies and Applications Market by Region: Revenue ($m), Market Share (%), 2014
  • Table 3.2 Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2014
  • Table 3.3 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 3.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2014-2019
  • Table 3.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2020-2025
  • Table 3.6 Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2019 and 2025
  • Table 4.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.2 Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2014
  • Table 4.3 Global HSCT Operations: Estimated Number of Operations by Donor Type, 2012-2014
  • Table 4.4 European HSCT Operations: Number of Operations by Donor Type, 2003-2012
  • Table 4.5 Indications with Medicare Coverage for HSCT, 2014
  • Table 4.6 Malignancies and Other Haematological Diseases Treated with HSCT, 2014
  • Table 4.7 HSCT-Addressable Cancers: Estimated Incidence in the Major Markets (Number of Cases), CAGR (%), 2012-2024
  • Table 4.8 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2014
  • Table 4.9 Stem Cell Cancer Therapeutics Pipeline, 2014
  • Table 4.10 Mesoblast: Prochymal Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.2 Global Cardiovascular Disease Market by Drug Class: Revenue ($bn), 2014
  • Table 5.3 Projected Global Deaths From Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
  • Table 5.4 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), 2012-2013
  • Table 5.5 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.6 Reliance Life Sciences: CardioRel Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.7 Stem Cell Cardiovascular Therapeutics: Phase 2 and Phase 3 Pipeline, 2014
  • Table 5.8 Stem Cell Cardiovascular Therapeutics: Preclinical and Phase 1 and 1/2 Pipeline, 2014
  • Table 6.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 6.2 Stem Cell CNS Therapeutics: Phase 2 and 3 Pipeline, 2014
  • Table 6.3 Stem Cell CNS Therapeutics: Phase 1 and 1/2 Pipeline, 2014
  • Table 6.4 Stem Cell CNS Therapeutics: Preclinical Pipeline, 2014
  • Table 7.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 7.2 Selected Currently Available Stem Cell Therapeutics for Other Diseases, 2014
  • Table 7.3 NuVasive: Osteocel Plus Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 7.4 Orthofix: Trinity Elite and Evolution Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 7.5 Medipost: Cartistem Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 7.6 Diseases Other than Cancers to be Treated with HSCT, 2014
  • Table 7.7 Processes and Mechanism of Bone Repair, 2014
  • Table 7.8 Stem Cell Therapeutics in Other Diseases: Phase 2 and 3 Pipeline, 2014
  • Table 7.9 Stem Cell Therapeutics in Other Diseases: Phase 1 and 1/2 Pipeline, 2014
  • Table 7.10 Stem Cell Therapeutics in Other Diseases: Preclinical Pipeline, 2014
  • Table 7.11 Selected Genetically Modified Stem Cell Therapies Pipeline, 2014
  • Table 8.1 Stem Cell Non-Therapeutic Applications Market by Activity: Revenue ($m), Market Share (%), 2014
  • Table 8.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 8.3 Selected US Stem Cell Banks, 2014
  • Table 8.4 Selected Non-US Stem Cell Banks, 2014
  • Table 8.5 Selected Stem Cell Supply and Processing Companies, 2014
  • Table 8.6 Selected Companies With Involvement in Stem Cell-Based Assays, 2014
  • Table 8.7 Selected Companies With Other Stem Cell-Related Activities, 2014
  • Table 9.1 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2025
  • Table 11.1 Stem Cell Therapy Late-Stage Pipeline, 2014

List of Figures

  • Figure 1.1 Estimated Numbers of European HSCT Operations, 2003-2014
  • Figure 1.2 Global Stem Cell Technologies and Applications Market Segmentation Overview, 2014
  • Figure 2.1 Timeline of Stem Cell Research, 1900-2014
  • Figure 3.1 Stem Cell Technologies and Applications Market: Market Shares (%) of Therapeutic and Non-Therapeutic Applications, 2014
  • Figure 3.2 Stem Cell Technologies and Applications Market: Market Share (%) by Region, 2014
  • Figure 3.3 Stem Cell Technologies and Applications Market by Segment: Market Share (%), 2014
  • Figure 3.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 3.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m) by Segment, 2014-2025
  • Figure 3.6 Stem Cell Technologies and Applications Market: Market Share (%) by Segment, 2019
  • Figure 3.7 Stem Cell Technologies and Applications Market: Market Share (%) by Segment, 2025
  • Figure 3.8 Stem Cell Technologies and Applications Market: Drivers and Restraints, 2015-2025
  • Figure 4.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 4.2 Global HSCT Operations by Donor Type, 2014
  • Figure 4.3 European HSCT Operations by Donor Type, 2003-2012
  • Figure 4.4 HSCT-Addressable Cancers: Estimated Incidence in the Major Markets (Number of Cases), 2012-2024
  • Figure 4.5 Mesoblast: Prochymal Revenue ($m), AGR (%), 2014-2025
  • Figure 4.6 Stem Cell Cancer Therapeutics Market: Drivers and Restraints, 2015-2025
  • Figure 5.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%),2014-2025
  • Figure 5.2 Global Cardiovascular Disease Market by Drug Class: Market Share (%), 2014
  • Figure 5.3 Projected Global Deaths From Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
  • Figure 5.4 Pharmicell: Hearticellgram-AMI Revenue ($m), 2012-2013
  • Figure 5.5 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), 2014-2025
  • Figure 5.6 Reliance Life Sciences: CardioRel Revenue ($m), AGR (%), 2014-2025
  • Figure 5.7 Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2015-2025
  • Figure 6.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 6.2 Stem Cell CNS Therapeutics Market: Drivers and Restraints, 2015-2025
  • Figure 7.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 7.2 NuVasive: Osteocel Plus Revenue ($m), AGR (%), 2014-2025
  • Figure 7.3 Orthofix: Trinity Elite and Evolution Revenue ($m), AGR (%), 2014-2025
  • Figure 7.4 Medipost: Cartistem Revenue ($m), AGR (%), 2014-2025
  • Figure 8.1 Stem Cell Non-Therapeutic Applications Market by Activity: Market Share (%), 2014
  • Figure 8.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 8.3 Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints, 2015-2025
  • Figure 9.1 Stem Cell Technologies and Applications Market: Strengths and Weaknesses, 2015-2025
  • Figure 9.2 Stem Cell Technologies and Applications Market: Opportunities and Threats, 2015-2025
  • Figure 9.3 Stem Cell Technologies and Applications Market: STEP Analysis, 2015-2025
  • Figure 9.4 World 65+ Population Forecast: Size (m), AGR (%), 2014-2025
  • Figure 11.1 Stem Cell Technologies and Applications Market Forecast: Revenues ($m) by Therapeutic and Non-Therapeutic Applications, 2014-2025

Companies Listed

  • 3-D Matrix
  • Adistem
  • Advanced Cell Technology
  • Ageless Regenerative Institute
  • Aldagen
  • Alder Biopharmaceuticals
  • Alkems
  • AllCells
  • Allergan
  • Alliancells Bioscience Corporation (subsidiary of Zhongyuan Union Stem Cell Bio-engineering)
  • AlloCure
  • Allosource
  • ALS Association
  • American Academy of Pediatrics (AAP)
  • American Board of Cosmetic Surgery
  • American Board of Otolaryngology/head and Neck Surgery
  • American College of Surgeons
  • American CryoStem
  • American Society of Blood and Marrow Transplantation
  • Americas Committee for Treatment and Research in Multiple Sclerosis
  • Americord
  • Amgen
  • Amorcyte
  • AngioCrine Bioscience
  • Angiotech Pharmaceuticals
  • Anterogen (subsidiary of Bukwang Pharm Co Ltd)
  • Antria
  • apceth
  • Aristotle University of Thessaloniki
  • Arteriocyte
  • Asterias Biotherapeutics (subsidiary of BioTime)
  • Athersys
  • Autogenesis
  • Axiogenesis
  • Baxter International
  • BaYi Brain Hospital (China)
  • Beike Biotechnology
  • Berkshire Hathaway
  • Beth Israel Deaconess Medical Center
  • BioCardia
  • BioE
  • BioEden
  • Biogen Idec
  • Biogenea-Cellgenea
  • Bioheart
  • Biologic Therapies
  • Biomatrica
  • Biomet
  • BioRestorative Therapies
  • Biotec Services International
  • BioTime
  • BioTime Asia (subsidiary of BioTime)
  • Blackstone Medical (acquired by Orthofix)
  • bluebird bio
  • Boston Children's Hospital
  • BrainStorm Cell Therapeutics
  • Bukwang Pharm Co Ltd
  • California Institute of Regenerative Medicine (CIRM)
  • California Institute of Technology (Caltech)
  • Calimmune
  • Cancer Research UK / Cancer Research Technology
  • Capricor
  • Cardio3 BioSciences
  • Cardiogenesis
  • Carolinas Cord Blood Bank
  • Casey Eye Institute, Oregon Health and Science University
  • Cedars-Sinai Heart Institute
  • Celgene
  • Celgene Cellular Therapeutics (formerly Anthrogenesis; subsidiary of Celgene)
  • Cell Cure Neurosciences (subsidiary of BioTime)
  • Cell Surgical Network
  • Cell Targeting (assets acquired by BioTime)
  • Cell Therapy Limited
  • Cellartis (subsidiary of Takara Bio)
  • CellCentric
  • Cellectis
  • Cellerant Therapeutics
  • Cellerix (merged with TiGenix)
  • Cellonis Biotechnologies
  • CellProthera
  • CellSeed
  • Cellular Biomedicine Group
  • Cellular Dynamics International (CDI)
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • Centers for Medicare & Medicaid Services (CMS)
  • Cephalon (part of Teva)
  • Cesca Therapeutics
  • CHA Biotech
  • Cha General Hospital (Seoul, South Korea)
  • Chicago Medical School
  • China Cord Blood Corporation
  • Chinese Academy of Sciences
  • Cipla
  • CJ CheilJedang
  • Cleveland Biolabs
  • ClinImmune Labs
  • Cognate BioServices
  • Consortium of Multiple Sclerosis Centers
  • Cook General BioTechnology
  • Cord Blood America
  • Cord Blood Registry Systems
  • Cordlife Group
  • CoreStem
  • CRISPR Therapeutics
  • Cryo-Cell International
  • CryoCord
  • Cryonix CJSC
  • Cryo-Save
  • CryoSite
  • CXR Biosciences
  • Cynata Therapeutics (formerly Eco Quest Ltd)
  • Cytori Therapeutics
  • Dendreon
  • Department of Biotechnology (India)
  • Dong-A Pharmaceuticals Co. (South Korea)
  • Duke University
  • Eli Lilly
  • EpiStem
  • ES Cell International (subsidiary of BioTime)
  • ESI BIO (subsidiary of BioTime)
  • European Group for Blood and Marrow Transplantation (EBMT)
  • European Haematology Association
  • European Medicines Agency (EMA)
  • Fate Therapeutics
  • FDS Pharma
  • Fondazione Centro San Raffaele
  • Fondazione Telethon
  • Forbion Capital Partners
  • Forticell Bioscience
  • Gamida Cell
  • Gemabank (Human Stem Cells Institute cord blood bank)
  • Genetrix Group
  • Genomics Institute, Novartis Research Foundation
  • Genzyme (part of Sanofi)
  • Geron Corporation
  • Gilead Sciences
  • GlobalStem
  • Globocan
  • GMP Unlimited
  • Grey Innovation
  • GSK
  • Hadassah Medical Center
  • Harvard Apparatus Regenerative Technology
  • Harvard Business School
  • Harvard Stem Cell Institute
  • Harvard University
  • Health Canada
  • Human Fertilisation and Embryology Authority (HFEA) (UK)
  • Human Stem Cells Institute (Russia)
  • ImmunoCellular Therapeutics
  • Immunovative Therapies
  • Insception Biosciences
  • Institute of Biomedical Research (Japan)
  • IntelliCell Biosciences
  • International Society for Stem Cell Research (ISSCR)
  • International Stem Cell Corporation (ISCO)
  • International Stemcell Services
  • Intrexon Corporation
  • Invivo Therapeutics
  • IPS Academia Japan
  • IRCCS San Raffaele Hospital
  • Israel Stem Cell Society
  • JCR Pharmaceuticals
  • Johann Wolfgang Goethe University Hospital
  • Johnson & Johnson
  • Karolinska Institute
  • Kreos Capital
  • Life Stem Genetics
  • Lifebank Cryogenics
  • LifebankUSA
  • LifeMap Sciences (subsidiary of BioTime)
  • LifeMap Solutions (owned by Lifemap Sciences)
  • LifeSouth Community Blood Centers
  • Lincoln Park Capital
  • Lonza
  • Massachusetts General Hospital
  • Maxcyte
  • Mayo Clinic
  • McLean Hospital
  • MedCell Bioscience
  • Medical Protective Company
  • Medicines and Healthcare Products Regulatory Agency (MHRA) (UK)
  • Medipost
  • Medistem (formerly Medistem Laboratories; acquired by Intrexon)
  • Medistem Panama
  • Medpace Inc.
  • Medtronic
  • Merck & Co.
  • Merck Millipore
  • Mesoblast
  • MetaCyte Business Lab
  • Miltenyi Biotec
  • Ministry of Economy, Trade and Industry (Japan)
  • Ministry of Food and Drug Safety (MFDS) (South Korea)
  • Ministry of Health (China)
  • Ministry of Science and Technology (China)
  • Monash University
  • Mount Sinai Hospital
  • Musculoskeletal Transplant Foundation
  • National Dental Pulp Laboratory (subsidiary of New England Cryogenic Center)
  • NeoStem
  • NeuralStem
  • NeuroGeneration
  • NeuroSearch
  • New England Cryogenic Center
  • New York Blood Center
  • New York Heart Association
  • Nippon Zoki Pharmaceutical
  • Northern Therapeutics
  • Novartis
  • NsGene
  • Nuo Therapeutics (formerly Cytomedix)
  • NuVasive
  • OncoCyte (subsidiary of BioTime)
  • Opexa Therapeutics
  • OrbusNeich
  • OrthoCyte (subsidiary of BioTime)
  • Orthofix
  • Osiris Therapeutics
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Pharmicell (formerly FCB-Pharmicell)
  • Pharmsynthez
  • Plasticell
  • Pluristem
  • Polyphor
  • Proneuron Biotechnologies
  • Q Therapeutics
  • Queen Mary University of London
  • Quest Biomedical
  • Recyte Therapeutics (subsidiary of BioTime)
  • Regenerative Medicine Institute of Tijuana
  • Regenerative Sciences
  • Regenerex
  • Regenetech
  • Regeneus
  • Reliance Life Sciences
  • ReNeuron
  • Renovo Neural
  • RenovoCyte (subsidiary of Cook General BioTechnology)
  • RepliCel Life Sciences
  • ReproCELL
  • RhinoCyte
  • RIKEN Center for Developmental Biology
  • Roche
  • Roslin Cellab
  • RTI Surgical
  • RUSNANO
  • Rutgers University
  • Samuel Lunenfeld Research Institute
  • San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)
  • SanBio
  • Saneron CCEL Therapeutics
  • Sanofi
  • Sao Paolo University Hospital
  • Schepens Eye Research Institute
  • S-Evans Biosciences
  • Singapore National Eye Centre
  • Sirna Therapeutics
  • Skye Orthobiologics
  • Society for Neuroscience
  • Spinesmith Partners
  • SSM Cardinal Glennon Children's Medical Center
  • St. Louis Cord Blood Bank
  • Stamina Foundation
  • Stem Cell Therapeutics
  • Stemcell Technologies
  • StemCells
  • StemCore
  • StemCyte
  • Stemedica Cell Technologies
  • StemGen
  • Stemina Biomarker Discovery
  • Stempeutics
  • SynBio (joint venture)
  • Takara Bio
  • TAP Biosystems (Sartorius Stedim Biotech)
  • Targazyme (formerly America Stem Cell)
  • Tel Aviv University
  • Teva
  • Texas Medical Board
  • Therapeutic Goods Administration (TGA) (Australia)
  • Theratechnologies
  • Tianhe Stem Cell Biotechnologies
  • TiGenix
  • Tong Yuan Stem Cell
  • TrakCel
  • Translational Biosciences (subsidiary of Medistem Panama)
  • UHV Technologies
  • UK Medical Research Council
  • uniQure
  • University College London
  • University of California San Francisco
  • University of Colorado
  • University of Heidelberg
  • University of Kyoto
  • University of Massachusetts
  • University of Miami
  • University of Milan
  • University of Minnesota
  • University of Washington
  • University of Wisconsin
  • Uppsala University Hospital
  • US Food and Drug Administration (FDA)
  • US National Institute of Allergy and Infectious Diseases (NIAID)
  • US National Institutes of Health (NIH)
  • US National Marrow Donor Program
  • US Patent and Trademark Office
  • Valeant
  • Vericel Corporation (formerly Aastrom Biosciences)
  • Vesta Therapeutics
  • ViaCord
  • ViaCyte (formerly NovoCell)
  • ViroMed Laboratories
  • Vitro Biopharma
  • WA Optimum Health Care
  • World Health Organization
  • Yale University
  • Yonsei University
  • Zhongyuan Union Stem Cell Bio-engineering
Back to Top